1. Repositori Institucional (O2)
  2. Recerca
  3. Ciencias de la salud
  4. Articles
Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10609/92581
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorLuciano, Juan Vicente-
dc.contributor.authorD'Amico, Francesco-
dc.contributor.authorCerdà Lafont, Marta-
dc.contributor.authorPEÑARRUBIA-MARÍA, M TERESA-
dc.contributor.authorKnapp, Martin-
dc.contributor.authorCuesta Vargas, Antonio Ignacio-
dc.contributor.authorSerrano Blanco, Antoni-
dc.contributor.authorGarcia-Campayo, Javier-
dc.contributor.otherUniversidad de Málaga-
dc.contributor.otherLondon School of Economics and Political Science-
dc.contributor.otherUniversitat Oberta de Catalunya (UOC)-
dc.date.accessioned2019-03-26T12:11:26Z-
dc.date.available2019-03-26T12:11:26Z-
dc.date.issued2014-10-01-
dc.identifier.citationLuciano Devis, J.V., D'Amico, F., Cerdà-Lafont, M., Peñarrubia-María, M.T., Knapp, M., Cuesta-Vargas, A.I., Serrano Blanco, A. & García-Campayo, J. (2014). Cost-utility of cognitive behavioral therapy versus U.S. food and drug administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Research and Therapy, 16(1). doi: 10.1186/s13075-014-0451-y-
dc.identifier.issn1478-6362MIAR
-
dc.identifier.urihttp://hdl.handle.net/10609/92581-
dc.description.abstractCognitive behavioral therapy (CBT) and U.S. Food and Drug Administration (FDA)-recommended pharmacologic treatments (RPTs; pregabalin, duloxetine, and milnacipran) are effective treatment options for fibromyalgia (FM) syndrome and are currently recommended by clinical guidelines. We compared the cost-utility from the healthcare and societal perspectives of CBT versus RPT (combination of pregabalin + duloxetine) and usual care (TAU) groups in the treatment of FM.en
dc.language.isoeng-
dc.publisherArthritis Research and Therapy-
dc.relation.ispartofArthritis Research and Therapy, 2014, 16(1)-
dc.relation.urihttps://arthritis-research.biomedcentral.com/articles/10.1186/s13075-014-0451-y-
dc.rightsCC BY-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.subjectcognitive behavioral therapyen
dc.subjectusual careen
dc.subjectfibromyalgiaen
dc.subjectpregabalinen
dc.subjectduloxetineen
dc.subjectterapia cognitiva conductuales
dc.subjectcuidado usuales
dc.subjectfibromialgiaes
dc.subjectpregabalinaes
dc.subjectduloxetinaes
dc.subjectteràpia cognitiva conductualca
dc.subjectatenció habitualca
dc.subjectpregabalinaca
dc.subjectduloxetinaca
dc.subject.lcshCognitionen
dc.titleCost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial-
dc.typeinfo:eu-repo/semantics/article-
dc.subject.lemacCognicióca
dc.subject.lcshesCogniciónes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.doi10.1186/s13075-014-0451-y-
dc.gir.idAR/xxx-
dc.type.versioninfo:eu-repo/semantics/publishedVersion-
Aparece en las colecciones: Articles
Articles cientÍfics

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
costutility.pdf763,27 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem
Comparte:
Impacto: Google Scholar Microsoft Academic
Exporta:
Consulta las estadísticas

Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons